Quality of life outcomes in APOLLO, the phase 3 trial of the RNAi therapeutic patisiran in patients with hereditary transthyretin-mediated amyloidosis

Laura Obici,John L. Berk,Alejandra González-Duarte,Teresa Coelho,Julian D. Gillmore,Hartmut Schmidt,Matthias Schilling,Taro Yamashita,Céline Labeyrie,Thomas H. Brannagan,Senda Ajroud-Driss,Peter D. Gorevic,Arnt V. Kristen,Jaclyn Franklin,Jihong Chen,Marianne Sweetser,Jing Jing Wang,David H. Adams

Quality of life outcomes in APOLLO, the phase 3 trial of the RNAi therapeutic patisiran in patients with hereditary transthyretin-mediated amyloidosis

2020

Laura Obici
John L. Berk
Alejandra González-Duarte
Teresa Coelho
Julian D. Gillmore
Hartmut Schmidt
Matthias Schilling
Taro Yamashita
Céline Labeyrie
Thomas H. Brannagan
Senda Ajroud-Driss
Peter D. Gorevic
Arnt V. Kristen
Jaclyn Franklin
Jihong Chen
Marianne Sweetser
Jing Jing Wang
David H. Adams

AbstractIntroduction: Hereditary transthyretin-mediated (hATTR) amyloidosis is a rare, fatal, multisystem disease leading to deteriorating quality of life (QOL). The impact of patisiran on QOL in p...

Keywords:

Oncology
Quality of life
Amyloidosis
Disease
Biochemistry
Internal medicine
Transthyretin
RNA interference
Medicine
Diabetes mellitus
multisystem disease
in patient

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations